| Year |
Citation |
Score |
| 2021 |
Stern AD, Chen JL, Ouellet M, Trusheim MR, El-Kilani Z, Jessup A, Berndt ER. Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users. Health Affairs (Project Hope). 40: 989-999. PMID 34097520 DOI: 10.1377/hlthaff.2020.02239 |
0.334 |
|
| 2020 |
Conti RM, Berndt ER. FOUR FACTS CONCERNING COMPETITION IN U.S. GENERIC PRESCRIPTION DRUG MARKETS. International Journal of the Economics of Business. 27: 27-48. PMID 33041629 DOI: 10.1080/13571516.2019.1654324 |
0.399 |
|
| 2020 |
Frank RG, Hicks A, Berndt ER. The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines. Medical Care Research and Review : McRr. 1077558720921100. PMID 32468959 DOI: 10.1177/1077558720921100 |
0.388 |
|
| 2019 |
Kaygisiz NB, Shivdasani Y, Conti RM, Berndt ER. The Geography of Prescription Pharmaceuticals Supplied to the U.S.: Levels, Trends and Implications National Bureau of Economic Research. DOI: 10.3386/W26524 |
0.412 |
|
| 2019 |
Adajar PM, Berndt ER, Conti RM. The Surprising Hybrid Pedigree of Measures of Diversity and Economic Concentration National Bureau of Economic Research. DOI: 10.3386/W26512 |
0.371 |
|
| 2018 |
Berndt ER, Conti RM, Murphy SJ. The generic drug user fee amendments: an economic perspective. Journal of Law and the Biosciences. 5: 103-141. PMID 29707218 DOI: 10.1093/Jlb/Lsy002 |
0.375 |
|
| 2018 |
Bosworth B, Bieler J, Kleinrock M, Koepcke E, Berndt ER. An Evaluation of the CPI Indexes for Prescription Drugs National Bureau of Economic Research. DOI: 10.3386/W24210 |
0.388 |
|
| 2017 |
Berndt ER, Conti RM, Murphy SJ. The Landscape of US Generic Prescription Drug Markets, 2004-2016 National Bureau of Economic Research. DOI: 10.3386/W23640 |
0.426 |
|
| 2016 |
Aitken M, Berndt ER, Cutler D, Kleinrock M, Maini L. Has The Era Of Slow Growth For Prescription Drug Spending Ended? Health Affairs (Project Hope). 35: 1595-603. PMID 27605638 DOI: 10.1377/Hlthaff.2015.1636 |
0.421 |
|
| 2016 |
Berndt ER, Dubois P. Impacts of Patent Expiry on Daily Cost of Pharmaceutical Treatments in Eight OECD Countries, 2004–2010 International Journal of the Economics of Business. 23: 125-147. DOI: 10.1080/13571516.2015.1122969 |
0.37 |
|
| 2015 |
Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the Market for Anticancer Drugs. The Journal of Economic Perspectives : a Journal of the American Economic Association. 29: 139-62. PMID 28441702 DOI: 10.1257/Jep.29.1.139 |
0.389 |
|
| 2015 |
Trusheim MR, Berndt ER. The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics. Drug Discovery Today. 20: 1439-50. PMID 26542060 DOI: 10.1016/J.Drudis.2015.10.017 |
0.324 |
|
| 2015 |
Anderson TS, Huskamp HA, Epstein AJ, Barry CL, Men A, Berndt ER, Horvitz-Lennon M, Normand SL, Donohue JM. Antipsychotic prescribing: do conflict of interest policies make a difference? Medical Care. 53: 338-45. PMID 25769055 DOI: 10.1097/Mlr.0000000000000329 |
0.348 |
|
| 2015 |
Berndt ER, Nass D, Kleinrock M, Aitken M. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Affairs (Project Hope). 34: 245-52. PMID 25646104 DOI: 10.1377/Hlthaff.2014.1029 |
0.404 |
|
| 2015 |
Berndt ER, Gibbons RS, Kolotilin A, Taub AL. The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics. Journal of Health Economics. 40: 26-39. PMID 25575344 DOI: 10.1016/J.Jhealeco.2014.11.003 |
0.327 |
|
| 2014 |
Berndt ER, Cockburn IM. The hidden cost of low prices: limited access to new drugs in India. Health Affairs (Project Hope). 33: 1567-75. PMID 25201661 DOI: 10.1377/Hlthaff.2013.1307 |
0.401 |
|
| 2013 |
Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. Medical Care. 51: 622-7. PMID 23604014 DOI: 10.1097/Mlr.0B013E318290216F |
0.307 |
|
| 2013 |
Kornfield R, Donohue J, Berndt ER, Alexander GC. Promotion of Prescription Drugs to Consumers and Providers, 2001-2010 Plos One. 8. PMID 23469165 DOI: 10.1371/Journal.Pone.0055504 |
0.374 |
|
| 2013 |
Trusheim MR, Austin MJ, Rausch C, Berndt ER. Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. Pharmacogenomics. 14: 325-34. PMID 23394394 DOI: 10.2217/Pgs.13.3 |
0.315 |
|
| 2013 |
Huskamp HA, O'Malley AJ, Horvitz-Lennon M, Taub AL, Berndt ER, Donohue JM. How quickly do physicians adopt new drugs? The case of second-generation antipsychotics. Psychiatric Services (Washington, D.C.). 64: 324-30. PMID 23280376 DOI: 10.1176/Appi.Ps.201200186 |
0.32 |
|
| 2013 |
Aitken ML, Berndt ER, Bosworth B, Cockburn IM, Frank R, Kleinrock M, Shapiro BT. The Regulation of Prescription Drug Competition and Market Responses: Patterns in Prices and Sales following Loss of Exclusivity National Bureau of Economic Research. 243-271. DOI: 10.3386/W19487 |
0.37 |
|
| 2012 |
Trusheim MR, Berndt ER. Economic challenges and possible policy actions to advance stratified medicine. Personalized Medicine. 9: 413-427. PMID 29776261 DOI: 10.2217/Pme.12.35 |
0.373 |
|
| 2012 |
Berndt ER, Newhouse JP. Pricing and Reimbursement in US Pharmaceutical Markets The Oxford Handbook of the Economics of the Biopharmaceutical Industry. DOI: 10.2139/Ssrn.1676213 |
0.425 |
|
| 2012 |
Arzaghi M, Berndt ER, Davis JC, Silk AJ. The unbundling of advertising agency services: An economic analysis Review of Marketing Science. 10. DOI: 10.1515/1546-5616.1164 |
0.308 |
|
| 2011 |
Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt ER, McAdams S. Advance market commitment for pneumococcal vaccines: putting theory into practice. Bulletin of the World Health Organization. 89: 913-8. PMID 22271949 DOI: 10.2471/Blt.11.087700 |
0.326 |
|
| 2011 |
Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, Lieftucht A, Mazumder A, Milloy J, Shaw PM, Swank D, Wang J, Berndt ER, Goodsaid F, Palmer MC. Quantifying factors for the success of stratified medicine Nature Reviews Drug Discovery. 10: 817-833. PMID 22037040 DOI: 10.1038/Nrd3557 |
0.334 |
|
| 2011 |
Snyder CM, Begor W, Berndt ER. Economic perspectives on the advance market commitment for pneumococcal vaccines. Health Affairs (Project Hope). 30: 1508-17. PMID 21821567 DOI: 10.1377/Hlthaff.2011.0403 |
0.313 |
|
| 2011 |
Berndt ER, McGuire T, Newhouse JP. A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets Forum For Health Economics & Policy. 14. DOI: 10.2202/1558-9544.1301 |
0.429 |
|
| 2011 |
Berndt ER, Blalock N, Cockburn IM. Diffusion of New Drugs in the Post-TRIPS Era International Journal of the Economics of Business. 18: 203-224. DOI: 10.1080/13571516.2011.584426 |
0.348 |
|
| 2011 |
Berndt ER, Aitken ML. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation International Journal of the Economics of Business. 18: 177-201. DOI: 10.1080/13571516.2011.584423 |
0.413 |
|
| 2010 |
Bollyky TJ, Cockburn IM, Berndt E. Bridging the Gap: Improving Clinical Development and the Regulatory Pathways for Health Products for Neglected Diseases Clinical Trials. 7: 719-734. PMID 21109581 DOI: 10.1177/1740774510386390 |
0.313 |
|
| 2010 |
Trusheim MR, Aitken ML, Berndt ER. Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? Forum For Health Economics & Policy. 13: 1-45. DOI: 10.2139/Ssrn.1880601 |
0.355 |
|
| 2009 |
Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Affairs (Project Hope). 28: w151-60. PMID 19088102 DOI: 10.1377/Hlthaff.28.1.W151 |
0.365 |
|
| 2008 |
Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG. Generic entry, reformulations and promotion of SSRIs in the US. Pharmacoeconomics. 26: 603-16. PMID 18563951 DOI: 10.2165/00019053-200826070-00007 |
0.398 |
|
| 2008 |
Arzaghi M, Berndt ER, Davis JC, Silk AJ. Economic Factors Underlying the Unbundling of Advertising Agency Services National Bureau of Economic Research. DOI: 10.2139/Ssrn.1458598 |
0.311 |
|
| 2008 |
Ling DC, Berndt ER, Frank RG. Economic Incentives And Contracts: The Use Of Psychotropic Medications Contemporary Economic Policy. 26: 49-72. DOI: 10.1111/J.1465-7287.2007.00063.X |
0.352 |
|
| 2008 |
Chwelos PD, Berndt ER, Cockburn IM. Faster, smaller, cheaper: an hedonic price analysis of PDAs Applied Economics. 40: 2839-2856. DOI: 10.1080/00036840600993924 |
0.375 |
|
| 2008 |
Thiers FA, Sinskey AJ, Berndt ER. Trends in the globalization of clinical trials Nature Reviews Drug Discovery. 7: 13-14. DOI: 10.1038/Nrd2441 |
0.308 |
|
| 2008 |
Philipson T, Berndt ER, Gottschalk AHB, Sun E. Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts Journal of Public Economics. 92: 1306-1325. DOI: 10.1016/J.Jpubeco.2007.09.010 |
0.394 |
|
| 2007 |
Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E. Authorized generic drugs, price competition, and consumers' welfare. Health Affairs (Project Hope). 26: 790-9. PMID 17485758 DOI: 10.1377/Hlthaff.26.3.790 |
0.388 |
|
| 2007 |
Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews. Drug Discovery. 6: 287-93. PMID 17380152 DOI: 10.1038/Nrd2251 |
0.335 |
|
| 2007 |
Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, Williams H. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Economics. 16: 491-511. PMID 17013993 DOI: 10.1002/Hec.1176 |
0.373 |
|
| 2007 |
Graham JB, Berndt ER. The December Effect in FDA Drug Approvals: Assessing the Submissions Echo Hypothesis Drug Information Journal. 41: 653-659. DOI: 10.1177/009286150704100512 |
0.319 |
|
| 2007 |
Berndt ER. A primer on the economics of re-importation of prescription drugs Managerial and Decision Economics. 28: 415-435. DOI: 10.1002/Mde.1348 |
0.385 |
|
| 2007 |
Berndt ER, Danzon PM, Kruse GB. Dynamic competition in pharmaceuticals: Cross-national evidence from new drug diffusion Managerial and Decision Economics. 28: 231-250. DOI: 10.1002/Mde.1338 |
0.345 |
|
| 2006 |
Berndt ER, Cockburn IM, Grépin KA. The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications. Pharmacoeconomics. 24: 69-86. PMID 23389490 DOI: 10.2165/00019053-200624002-00008 |
0.333 |
|
| 2006 |
Berndt ER, Busch AB, Frank RG, Normand S. Real Output in Mental Health Care during the 1990s Forum For Health Economics & Policy. 9. DOI: 10.2202/1558-9544.1040 |
0.302 |
|
| 2006 |
Berndt ER, Gottschalk AHB, Strobeck MW. Opportunities for Improving the Drug Development Process: Results from a Survey of Industry and the Fda Innovation Policy and the Economy. 6: 91-122. DOI: 10.1086/Ipe.6.25056181 |
0.367 |
|
| 2005 |
Berndt ER, Gottschalk AH, Philipson TJ, Strobeck MW. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nature Reviews. Drug Discovery. 4: 545-54. PMID 16052239 DOI: 10.1038/Nrd1774 |
0.335 |
|
| 2005 |
Berndt ER, Hurvitz JA. Vaccine advance-purchase agreements for low-income countries: practical issues. Health Affairs (Project Hope). 24: 653-65. PMID 15886157 DOI: 10.1377/Hlthaff.24.3.653 |
0.301 |
|
| 2005 |
Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH. The impact of anaemia and its treatment on employee disability and medical costs Pharmacoeconomics. 23: 183-192. PMID 15748092 DOI: 10.2165/00019053-200523020-00009 |
0.302 |
|
| 2005 |
Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. The New England Journal of Medicine. 352: 325-8. PMID 15673797 DOI: 10.1056/Nejmp048357 |
0.319 |
|
| 2005 |
Philipson TJ, Berndt ER, Gottschalk AHB, Strobeck MW. Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts National Bureau of Economic Research. DOI: 10.3386/W11724 |
0.383 |
|
| 2005 |
White AG, Abel JR, Berndt ER, Monroe CW. Hedonic Price Indexes for Personal Computer Operating Systems and Productivity Suites Annals of Economics and Statistics. 787-807. DOI: 10.2307/20777597 |
0.334 |
|
| 2005 |
Berndt ER, Gottschalk AHB, Philipson T, Strobeck MW. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process Forum For Health Economics & Policy. 8. DOI: 10.2202/1558-9544.1013 |
0.32 |
|
| 2005 |
Berndt ER, Glennerster R, Kremer M, Lee J, Levine R, Weizsacker G, Williams HL. Advanced purchase commitments for a malaria vaccine: estimating costs and effectiveness Lse Research Online Documents On Economics. DOI: 10.2139/Ssrn.696741 |
0.31 |
|
| 2005 |
Stoker TM, Berndt ER, Ellerman AD, Schennach SM. Panel data analysis of U.S. coal productivity Journal of Econometrics. 127: 131-164. DOI: 10.1016/J.Jeconom.2004.06.006 |
0.305 |
|
| 2004 |
Lerner D, Adler DA, Chang H, Berndt ER, Irish JT, Lapitsky L, Hood MY, Reed J, Rogers WH. The clinical and occupational correlates of work productivity loss among employed patients with depression. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 46: S46-55. PMID 15194895 DOI: 10.1097/01.Jom.0000126684.82825.0A |
0.318 |
|
| 2004 |
Berndt ER. Unique issues raised by drug benefit design. Health Affairs (Project Hope). 23: 103-6. PMID 15002632 DOI: 10.1377/Hlthaff.23.1.103 |
0.353 |
|
| 2004 |
Silk AJ, Berndt ER. Holding Company Cost Economies in the Global Advertising and Marketing Services Business Review of Marketing Science. 2: 1-51. DOI: 10.2202/1546-5616.1015 |
0.38 |
|
| 2004 |
Donohue JM, Berndt ER. Effects of direct-to-consumer advertising on medication choice: The case of antidepressants Journal of Public Policy and Marketing. 23: 115-127. DOI: 10.1509/Jppm.23.2.115.51395 |
0.315 |
|
| 2003 |
Lerner D, Amick BC, Lee JC, Rooney T, Rogers WH, Chang H, Berndt ER. Relationship of employee-reported work limitations to work productivity. Medical Care. 41: 649-59. PMID 12719689 DOI: 10.1097/01.Mlr.0000062551.76504.A9 |
0.31 |
|
| 2003 |
Abel JR, Berndt ER, White AG. Price Indexes for Microsoft's Personal Computer Software Products National Bureau of Economic Research. DOI: 10.3386/W9966 |
0.376 |
|
| 2003 |
Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank RG. Demand Effects of Recent Changes in Prescription Drug Promotion Forum For Health Economics & Policy. 6: 1-26. DOI: 10.2202/1558-9544.1044 |
0.373 |
|
| 2003 |
Silk AJ, Berndt ER. Scale and Scope Economies in the Global Advertising and Marketing Services Business National Bureau of Economic Research. DOI: 10.2139/Ssrn.462240 |
0.379 |
|
| 2003 |
Berndt ER, Pindyck RS, Azoulay P. Consumption Externalities and Diffusion in Pharmaceutical Markets: Antiulcer Drugs Journal of Industrial Economics. 51: 243-270. DOI: 10.1111/1467-6451.00200 |
0.375 |
|
| 2002 |
Crown WH, Ling D, Berndt E. Measuring the costs and benefits of pharmaceutical expenditures. Expert Review of Pharmacoeconomics & Outcomes Research. 2: 467-75. PMID 19807470 DOI: 10.1586/14737167.2.5.467 |
0.362 |
|
| 2002 |
Berndt ER. Pharmaceuticals in U.S. health care: determinants of quantity and price. The Journal of Economic Perspectives : a Journal of the American Economic Association. 16: 45-66. PMID 15179978 DOI: 10.1257/089533002320950975 |
0.432 |
|
| 2002 |
Berndt ER, Bir A, Busch SH, Frank RG, Normand SL. The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexes. Journal of Health Economics. 21: 373-96. PMID 12022264 DOI: 10.1016/S0167-6296(01)00132-1 |
0.355 |
|
| 2002 |
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. The New England Journal of Medicine. 346: 498-505. PMID 11844852 DOI: 10.1056/Nejmsa012075 |
0.35 |
|
| 2002 |
Ling DC, Berndt ER, Kyle MK. Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales* The Journal of Law and Economics. 45: 691-723. DOI: 10.1086/368004 |
0.385 |
|
| 2002 |
Silk AJ, Klein LR, Berndt ER. Intermedia substitutability and market demand by national advertisers Review of Industrial Organization. 20: 323-348. DOI: 10.1023/A:1015653227386 |
0.364 |
|
| 2001 |
Berndt ER. The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment? Health Affairs. 20: 100-114. PMID 11260932 DOI: 10.1377/Hlthaff.20.2.100 |
0.424 |
|
| 2001 |
Berndt ER, Rappaport NJ. Price and Quality of Desktop and Mobile Personal Computers: A Quarter-Century Historical Overview The American Economic Review. 91: 268-273. DOI: 10.1257/Aer.91.2.268 |
0.36 |
|
| 2001 |
Busch SH, Berndt ER, Frank RG. Creating Price Indexes for Measuring Productivity in Mental Health Care Forum For Health Economics & Policy. 4: 115-147. DOI: 10.1162/10962310152434298 |
0.375 |
|
| 2001 |
Silk AJ, Klein LR, Berndt ER. The Emerging Position of the Internet as an Advertising Medium Netnomics. 3: 129-148. DOI: 10.1023/A:1011455329830 |
0.337 |
|
| 2000 |
Berndt ER, Russell JM, Miceli R, Colucci SV, Xu Y, Grudzinski AN. Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 3: 208-21. PMID 16464185 DOI: 10.1046/J.1524-4733.2000.33001.X |
0.348 |
|
| 2000 |
Berndt ER. International comparisons of pharmaceutical prices: what do we know, and what does it mean? Journal of Health Economics. 19: 283-287. PMID 10947581 DOI: 10.1016/S0167-6296(99)00043-0 |
0.355 |
|
| 2000 |
Berndt ER, Bailit HL, Keller MB, Verner JC, Finkelstein SN. Health care use and at-work productivity among employees with mental disorders. Health Affairs (Project Hope). 19: 244-56. PMID 10916980 DOI: 10.1377/Hlthaff.19.4.244 |
0.321 |
|
| 2000 |
Berndt ER, Cutler DM, Frank RG, Griliches Z, Newhouse JP, Triplett JE. Chapter 3 Medical care prices and output Handbook of Health Economics. 1: 119-180. DOI: 10.1016/S1574-0064(00)80162-6 |
0.372 |
|
| 1999 |
Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. Journal of Occupational and Environmental Medicine. 41: 948-953. PMID 10570499 DOI: 10.1097/00043764-199911000-00005 |
0.308 |
|
| 1999 |
Berndt ER, Pindyck RS, Azoulay P. Network effects and diffusion in pharmaceutical markets : antiulcer drugs National Bureau of Economic Research. DOI: 10.3386/W7024 |
0.374 |
|
| 1998 |
Berndt ER, Cutler DM, Frank RG, Griliches Z, Newhouse JP, Triplett JE. Price Indexes for Medical Care Goods and Services: An Overview of Measurement Issues National Bureau of Economic Research. 141-200. DOI: 10.3386/W6817 |
0.37 |
|
| 1998 |
Berndt ER, Busch SH, Frank RG. Price Indexes for Acute Phase Treatment of Depression National Bureau of Economic Research. DOI: 10.3386/W6799 |
0.354 |
|
| 1998 |
Frank RG, Berndt ER, Busch SH. Price Indexes for the Treatment of Depression National Bureau of Economic Research. DOI: 10.3386/W6417 |
0.383 |
|
| 1998 |
Berndt ER, Cockburn IM, Cocks DL, Epstein AM, Griliches Z. Is Price Inflation Different for the Elderly? An Empirical Analysis of Prescription Drugs Forum For Health Economics & Policy. 1: 33-76. DOI: 10.2202/1558-9544.1057 |
0.383 |
|
| 1996 |
Berndt ER, Frank RG, McGuire TG. Alternate Insurance Arrangements and the Treatment of Depression: What are the Facts? The American Journal of Managed Care. 3: 243. DOI: 10.3386/W5813 |
0.35 |
|
| 1995 |
Berndt ER, Malone TW. Guest editors’ introduction to special issue: Information technology and the productivity paradox: Getting the questions right Economics of Innovation and New Technology. 3: 177-182. DOI: 10.1080/10438599500000001 |
0.568 |
|
| 1995 |
Berndt ER, Griliches Z, Rappaport NJ. Econometric estimates of price indexes for personal computers in the 1990's Journal of Econometrics. 68: 243-268. DOI: 10.1016/0304-4076(94)01651-F |
0.36 |
|
| 1995 |
Berndt ER, Morrison CJ. High-tech capital formation and economic performance in U.S. manufacturing industries : an exploratory analysis Journal of Econometrics. 65: 9-43. DOI: 10.1016/0304-4076(94)01596-R |
0.359 |
|
| 1994 |
Berndt ER, Bui LT, Reiley D, Urban GL. The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry National Bureau of Economic Research. 277-328. DOI: 10.7208/9780226074184-009 |
0.398 |
|
| 1994 |
Silk AJ, Berndt ER. Costs, Institutional Mobility Barriers, and Market Structure: Advertising Agencies as Multiproduct Firms Journal of Economics and Management Strategy. 3: 437-480. DOI: 10.1111/J.1430-9134.1994.00437.X |
0.395 |
|
| 1993 |
Berndt E, Kolstad C, Lee J. Measuring the Energy Efficiency and Productivity Impacts of Embodied Technical Change The Energy Journal. 14. DOI: 10.5547/Issn0195-6574-Ej-Vol14-No1-2 |
0.32 |
|
| 1993 |
Silk AJ, Berndt ER. Scale and Scope Effects on Advertising Agency Costs Marketing Science. 12: 53-72. DOI: 10.1287/Mksc.12.1.53 |
0.371 |
|
| 1993 |
Berndt ER, Griliches Z, Rosett JG. Auditing the Producer Price Index: Micro Evidence from Prescription Pharmaceutical Preparations Journal of Business & Economic Statistics. 11: 251-264. DOI: 10.1080/07350015.1993.10509953 |
0.37 |
|
| 1993 |
Berndt ER, Friedlaender AF, Chiang JSW, Vellturo CA. Cost Effects of Mergers and Deregulation in the U.S. Rail Industry Journal of Productivity Analysis. 4: 127-144. DOI: 10.1007/Bf01073470 |
0.341 |
|
| 1992 |
Berndt ER, Morrison CJ, Rosenblum LS. High-Tech Capital Formation and Labor Composition in U.S. Manufacturing Industries: An Exploratory Analysis National Bureau of Economic Research. DOI: 10.3386/W4010 |
0.301 |
|
| 1992 |
Berndt ER, Hansson B. Measuring the Contribution of Public Infrastructure Capital in Sweden The Scandinavian Journal of Economics. 94: 151-168. DOI: 10.2307/3440255 |
0.366 |
|
| 1991 |
Friedlaender AF, Berndt ER, Chiang JSW, Showalter M, Vellturo CA. Rail Costs and Capital Adjustments in a Quasi-Regulated Environment Journal of Transport Economics and Policy. 27. DOI: 10.3386/W3841 |
0.343 |
|
| 1991 |
Berndt ER, Friedlaender AF, Chiang JSW, Vellturo CA. Mergers, Deregulation and Cost Savings in the U.S. Rail Industry National Bureau of Economic Research. DOI: 10.3386/W3749 |
0.371 |
|
| 1990 |
Berndt ER, Griliches Z. Price Indexes for Microcomputers: An Exploratory Study National Bureau of Economic Research. 63-100. DOI: 10.7208/9780226257327-004 |
0.345 |
|
| 1990 |
Berndt ER, Griliches Z, Rosett JG. On the Accuracy of Producer Price Indexes for Pharmaceutical Preparations: An Audit Based on Detailed Firm-Specific Data National Bureau of Economic Research. DOI: 10.3386/W3490 |
0.393 |
|
| 1990 |
Berndt ER, Friedlaender AF, Chiang JSW. Interdependent Pricing and Markup Behavior: an Empirical Analysis of GM, Ford and Chrysler National Bureau of Economic Research. DOI: 10.3386/W3396 |
0.308 |
|
| 1990 |
Berndt ER. Energy use, technical progress and productivity growth: A survey of economic issues Journal of Productivity Analysis. 2: 67-83. DOI: 10.1007/Bf00158709 |
0.326 |
|
| 1989 |
Berndt ER, Fuss MA. Economic Capacity Utilization and Productivity Measurement for Multi-Product Firms with Multiple Quasi-Fixed Inputs National Bureau of Economic Research. DOI: 10.3386/W2932 |
0.336 |
|
| 1986 |
Berndt ER, Wood DO. Energy Price Shocks And Productivity Growth In Us And Uk Manufacturing Oxford Review of Economic Policy. 2: 1-31. DOI: 10.1093/Oxrep/2.3.1-A |
0.343 |
|
| 1986 |
Berndt ER, Hesse DM. Measuring and assessing capacity utilization in the manufacturing sectors of nine oecd countries European Economic Review. 30: 961-989. DOI: 10.1016/S0014-2921(86)80001-0 |
0.378 |
|
| 1986 |
Berndt ER, Fuss MA. Productivity measurement with adjustments for variations in capacity utilization and other forms of temporary equilibrium Journal of Econometrics. 33: 7-29. DOI: 10.1016/0304-4076(86)90025-4 |
0.365 |
|
| 1982 |
Berndt ER, Fuss MA. Productivity Measurement Using Capital Asset Valuation to Adjust for Variations in Utilization National Bureau of Economic Research. DOI: 10.3386/W0895 |
0.378 |
|
| 1979 |
Berndt ER, Sharp KC, Watkins GC. Utility Bond Rates and Tax Normalization Journal of Finance. 34: 1211-1220. DOI: 10.1111/J.1540-6261.1979.Tb00066.X |
0.337 |
|
| 1979 |
Berndt ER, Khaled MS. Parametric Productivity Measurement and Choice among Flexible Functional Forms Journal of Political Economy. 87: 1220-1245. DOI: 10.1086/260833 |
0.363 |
|
| 1979 |
Berndt ER, Morrisson CJ. Income redistribution and employment effects of rising energy prices Resources and Energy. 2: 131-150. DOI: 10.1016/0165-0572(79)90026-4 |
0.353 |
|
| 1978 |
Berndt ER. Aggregate Energy, Efficiency, and Productivity Measurement Annual Review of Energy. 3: 225-273. DOI: 10.1146/Annurev.Eg.03.110178.001301 |
0.348 |
|
| 1978 |
Berndt ER, Jorgenson DW. How energy, and its cost, enter the `productivity equation¿ Ieee Spectrum. 15: 50-52. DOI: 10.1109/Mspec.1978.6367905 |
0.577 |
|
| 1976 |
Berndt ER. Reconciling Alternative Estimates of the Elasticity of Substitution The Review of Economics and Statistics. 58: 59-68. DOI: 10.2307/1936009 |
0.337 |
|
| 1975 |
Berndt ER, Wood DO. Technology, Prices, and the Derived Demand for Energy The Review of Economics and Statistics. 57: 259-268. DOI: 10.2307/1923910 |
0.347 |
|
| 1973 |
Berndt ER, Christensen LR. The Internal Structure of Functional Relationships: Separability, Substitution, and Aggregation The Review of Economic Studies. 40: 403-410. DOI: 10.2307/2296459 |
0.633 |
|
| 1973 |
Berndt ER, Christensen LR. The translog function and the substitution of equipment, structures, and labor in U.S. manufacturing 1929-68 Journal of Econometrics. 1: 81-113. DOI: 10.1016/0304-4076(73)90007-9 |
0.625 |
|
| Show low-probability matches. |
